Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 256–257 (1 March 2008) | doi:10.1038/nbt0308-256c
Investor malaise stalks UK, European biotech
Abstract
As the dust settles on 2007's stock market performance, two things are clear. First, the European biotech sector lost significant value compared with the US industry.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
